Bigmar Announces 2000 Results

Net Loss Per Share Narrows to $.50 for Year End 2000

From a Loss of $.73 For Year End 1999



Apr 03, 2001, 01:00 ET from Bigmar, Inc.

    JOHNSTOWN, Ohio, April 3 /PRNewswire/ -- Bigmar, Inc.
 (OTC Bulletin Board:   BGMR.OB) has announced financial results for the year
 ended December 31, 2000.
     The company reported net sales for the year ended December 31, 2000 of
 $7,650,665, compared to $7,725,362 for the year ended December 31, 1999.  Year
 2000 revenues were adversely affected by the increase of the US Dollar
 exchange rate against the Swiss Franc.  Without taking the exchange rate
 increase into account, sales levels would have increased from approximately
 $7.73 million in 1999 to approximately $8.84 million in the year 2000, a
 14.4% increase or approximately $1.11 million.
     Gross margins increased from 16.4% in 1999 to 18.1% in the year 2000,
 while net losses per share narrowed to $.50 in the year ended December 31,
 2000 compared to a $.73 per share loss in the year ended December 31, 1999.
     "The narrowing of losses and increased margins was due primarily to
 managements efforts to contain costs related to its Barbengo Facility.  The
 company anticipates that gross margin levels should continue to improve as
 manufacturing levels increase," said John Tramontana, Bigmar's Chairman and
 CEO.  "We intend in 2001 to generate increased revenue growth by adding
 additional products, expanding market share, and increasing capacity," he
 said.
     Bigmar is a manufacturer of generic pharmaceutical oncology products and
 intravenous infusion solutions, which it manufactures at its state-of-the-art
 facilities in Switzerland.  The company markets its products through
 partnerships of pharmaceutical distributors in Europe and the United States
 and focuses on off-patent oncological pharmaceuticals.  For more information,
 please visit the company's Website, www.bgmr.com
     Statements in this press release that are not strictly historical may be
 "forward looking" statements, which involve risks and uncertainties.  No
 assurance can be given that the Company will successfully develop or
 commercialize its products, complete clinical trials, obtain regulatory
 approvals (or that and such approvals will be obtained on a timely basis) or
 be able to manufacture or successfully commercialize such products.  Actual
 results may differ from those described in this press release due to risks and
 uncertainties that exist in the Company's operations, including, without
 limitation, the ability to obtain additional financing to continue operations
 when needed, a history of operating losses and accumulated deficits, the
 Company's reliance on collaborative relationships, and uncertainties related
 to clinical trials, the ability to obtain the appropriate regulatory approvals
 and market acceptance, as well as other risks detailed from time to time in
 public available filings with the Securities and Exchange Commission such as
 the Company's Annual Report on Form 10-KSB and its most recent Registration
 Statement on Form S-3.  Actual results may differ materially from those
 currently anticipated as a result of such risks, and results for interim
 periods are not necessarily indicative of results to be expected for the full
 year.  The Company undertakes no obligation to release publicly the results of
 any revision to these forward-looking statements to reflect events or
 circumstances arising after the date hereof.  These statements are made
 pursuant to the Safe Harbor provisions of the Securities Litigation Act of
 1995.
 
 

SOURCE Bigmar, Inc.
    JOHNSTOWN, Ohio, April 3 /PRNewswire/ -- Bigmar, Inc.
 (OTC Bulletin Board:   BGMR.OB) has announced financial results for the year
 ended December 31, 2000.
     The company reported net sales for the year ended December 31, 2000 of
 $7,650,665, compared to $7,725,362 for the year ended December 31, 1999.  Year
 2000 revenues were adversely affected by the increase of the US Dollar
 exchange rate against the Swiss Franc.  Without taking the exchange rate
 increase into account, sales levels would have increased from approximately
 $7.73 million in 1999 to approximately $8.84 million in the year 2000, a
 14.4% increase or approximately $1.11 million.
     Gross margins increased from 16.4% in 1999 to 18.1% in the year 2000,
 while net losses per share narrowed to $.50 in the year ended December 31,
 2000 compared to a $.73 per share loss in the year ended December 31, 1999.
     "The narrowing of losses and increased margins was due primarily to
 managements efforts to contain costs related to its Barbengo Facility.  The
 company anticipates that gross margin levels should continue to improve as
 manufacturing levels increase," said John Tramontana, Bigmar's Chairman and
 CEO.  "We intend in 2001 to generate increased revenue growth by adding
 additional products, expanding market share, and increasing capacity," he
 said.
     Bigmar is a manufacturer of generic pharmaceutical oncology products and
 intravenous infusion solutions, which it manufactures at its state-of-the-art
 facilities in Switzerland.  The company markets its products through
 partnerships of pharmaceutical distributors in Europe and the United States
 and focuses on off-patent oncological pharmaceuticals.  For more information,
 please visit the company's Website, www.bgmr.com
     Statements in this press release that are not strictly historical may be
 "forward looking" statements, which involve risks and uncertainties.  No
 assurance can be given that the Company will successfully develop or
 commercialize its products, complete clinical trials, obtain regulatory
 approvals (or that and such approvals will be obtained on a timely basis) or
 be able to manufacture or successfully commercialize such products.  Actual
 results may differ from those described in this press release due to risks and
 uncertainties that exist in the Company's operations, including, without
 limitation, the ability to obtain additional financing to continue operations
 when needed, a history of operating losses and accumulated deficits, the
 Company's reliance on collaborative relationships, and uncertainties related
 to clinical trials, the ability to obtain the appropriate regulatory approvals
 and market acceptance, as well as other risks detailed from time to time in
 public available filings with the Securities and Exchange Commission such as
 the Company's Annual Report on Form 10-KSB and its most recent Registration
 Statement on Form S-3.  Actual results may differ materially from those
 currently anticipated as a result of such risks, and results for interim
 periods are not necessarily indicative of results to be expected for the full
 year.  The Company undertakes no obligation to release publicly the results of
 any revision to these forward-looking statements to reflect events or
 circumstances arising after the date hereof.  These statements are made
 pursuant to the Safe Harbor provisions of the Securities Litigation Act of
 1995.
 
 SOURCE  Bigmar, Inc.